Exagen Total Liab vs Current Deferred Revenue Analysis

XGN Stock

USD 1.90 0.03 1.60%

Exagen financial indicator trend analysis is much more than just examining Exagen Inc latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Exagen Inc is a good investment. Please check the relationship between Exagen Total Liab and its Current Deferred Revenue accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

Total Liab vs Current Deferred Revenue

Total Liab vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Exagen Inc Total Liab account and Current Deferred Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between Exagen's Total Liab and Current Deferred Revenue is 0.75. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Exagen Inc, assuming nothing else is changed. The correlation between historical values of Exagen's Total Liab and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Exagen Inc are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Total Liab i.e., Exagen's Total Liab and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.75

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Exagen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Exagen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

At this time, Exagen's Tax Provision is very stable compared to the past year. As of the 22nd of May 2024, Enterprise Value is likely to grow to about 27.9 M, while Selling General Administrative is likely to drop about 30.6 M.

	2021	2022	2023	2024 (projected)
Interest Expense	2.6M	2.4M	2.3M	2.8M
Depreciation And Amortization	16K	830K	2.2M	2.3M

Interest Expense Depreciation And Amortization

Exagen fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.7	0.81	-0.1	0.95	0.54	0.31	-0.94	-0.71	0.65	1.0	0.33	-0.39	1.0	-0.33	0.54	0.86	0.81	0.94	0.91	0.67	0.45	1.0	-0.35	0.83	0.7
Short Long Term Debt Total	0.7		0.83	0.38	0.44	0.58	0.7	-0.41	-0.79	0.88	0.67	0.5	0.14	0.67	-0.42	0.23	0.65	0.78	0.78	0.64	0.99	0.49	0.69	0.06	0.54	0.73
Other Current Liab	0.81	0.83		0.02	0.66	0.63	0.49	-0.62	-0.91	0.87	0.78	0.23	-0.28	0.78	-0.52	0.34	0.82	0.86	0.82	0.85	0.8	0.61	0.81	-0.32	0.74	0.89
Total Current Liabilities	-0.1	0.38	0.02		-0.32	0.04	0.56	0.32	0.0	0.37	-0.14	0.59	0.92	-0.14	-0.01	0.26	-0.07	-0.27	-0.08	-0.08	0.47	0.04	-0.13	0.93	-0.11	0.13
Total Stockholder Equity	0.95	0.44	0.66	-0.32		0.43	0.06	-1.0	-0.55	0.43	0.96	0.17	-0.57	0.96	-0.23	0.56	0.79	0.69	0.85	0.86	0.39	0.34	0.95	-0.5	0.8	0.55
Property Plant And Equipment Net	0.54	0.58	0.63	0.04	0.43		0.26	-0.37	-0.84	0.66	0.5	0.67	-0.06	0.5	-0.94	0.5	0.8	0.56	0.57	0.73	0.56	0.95	0.51	-0.19	0.71	0.82
Current Deferred Revenue	0.31	0.7	0.49	0.56	0.06	0.26		-0.07	-0.46	0.64	0.28	0.38	0.38	0.28	-0.2	0.07	0.28	0.38	0.34	0.26	0.75	0.25	0.29	0.36	0.2	0.44
Net Debt	-0.94	-0.41	-0.62	0.32	-1.0	-0.37	-0.07		0.51	-0.39	-0.95	-0.15	0.56	-0.95	0.18	-0.55	-0.76	-0.65	-0.82	-0.82	-0.37	-0.29	-0.94	0.47	-0.78	-0.51
Retained Earnings	-0.71	-0.79	-0.91	0.0	-0.55	-0.84	-0.46	0.51		-0.84	-0.67	-0.38	0.21	-0.67	0.79	-0.34	-0.89	-0.81	-0.74	-0.81	-0.76	-0.86	-0.7	0.32	-0.8	-0.92
Accounts Payable	0.65	0.88	0.87	0.37	0.43	0.66	0.64	-0.39	-0.84		0.61	0.53	0.08	0.61	-0.55	0.41	0.72	0.68	0.74	0.74	0.88	0.62	0.63	0.05	0.63	0.85
Cash	1.0	0.67	0.78	-0.14	0.96	0.5	0.28	-0.95	-0.67	0.61		0.28	-0.42	1.0	-0.28	0.52	0.83	0.79	0.93	0.89	0.62	0.4	1.0	-0.37	0.81	0.66
Non Current Assets Total	0.33	0.5	0.23	0.59	0.17	0.67	0.38	-0.15	-0.38	0.53	0.28		0.5	0.28	-0.51	0.56	0.4	0.13	0.32	0.4	0.55	0.54	0.28	0.46	0.33	0.5
Non Currrent Assets Other	-0.39	0.14	-0.28	0.92	-0.57	-0.06	0.38	0.56	0.21	0.08	-0.42	0.5		-0.42	0.02	0.08	-0.31	-0.48	-0.35	-0.34	0.23	-0.06	-0.42	0.95	-0.34	-0.09
Cash And Short Term Investments	1.0	0.67	0.78	-0.14	0.96	0.5	0.28	-0.95	-0.67	0.61	1.0	0.28	-0.42		-0.28	0.52	0.83	0.79	0.93	0.89	0.62	0.4	1.0	-0.37	0.81	0.66
Good Will	-0.33	-0.42	-0.52	-0.01	-0.23	-0.94	-0.2	0.18	0.79	-0.55	-0.28	-0.51	0.02	-0.28		-0.44	-0.73	-0.4	-0.38	-0.6	-0.41	-0.98	-0.31	0.18	-0.67	-0.76
Common Stock Total Equity	0.54	0.23	0.34	0.26	0.56	0.5	0.07	-0.55	-0.34	0.41	0.52	0.56	0.08	0.52	-0.44		0.65	0.08	0.47	0.71	0.26	0.48	0.52	0.18	0.71	0.54
Common Stock Shares Outstanding	0.86	0.65	0.82	-0.07	0.79	0.8	0.28	-0.76	-0.89	0.72	0.83	0.4	-0.31	0.83	-0.73	0.65		0.71	0.84	0.94	0.62	0.81	0.85	-0.34	0.98	0.85
Non Current Liabilities Total	0.81	0.78	0.86	-0.27	0.69	0.56	0.38	-0.65	-0.81	0.68	0.79	0.13	-0.48	0.79	-0.4	0.08	0.71		0.86	0.73	0.72	0.47	0.81	-0.57	0.62	0.69
Other Current Assets	0.94	0.78	0.82	-0.08	0.85	0.57	0.34	-0.82	-0.74	0.74	0.93	0.32	-0.35	0.93	-0.38	0.47	0.84	0.86		0.88	0.73	0.45	0.94	-0.34	0.81	0.67
Other Stockholder Equity	0.91	0.64	0.85	-0.08	0.86	0.73	0.26	-0.82	-0.81	0.74	0.89	0.4	-0.34	0.89	-0.6	0.71	0.94	0.73	0.88		0.61	0.68	0.9	-0.34	0.92	0.87
Total Liab	0.67	0.99	0.8	0.47	0.39	0.56	0.75	-0.37	-0.76	0.88	0.62	0.55	0.23	0.62	-0.41	0.26	0.62	0.72	0.73	0.61		0.49	0.65	0.15	0.52	0.72
Property Plant And Equipment Gross	0.45	0.49	0.61	0.04	0.34	0.95	0.25	-0.29	-0.86	0.62	0.4	0.54	-0.06	0.4	-0.98	0.48	0.81	0.47	0.45	0.68	0.49		0.42	-0.19	0.74	0.82
Total Current Assets	1.0	0.69	0.81	-0.13	0.95	0.51	0.29	-0.94	-0.7	0.63	1.0	0.28	-0.42	1.0	-0.31	0.52	0.85	0.81	0.94	0.9	0.65	0.42		-0.38	0.83	0.68
Short Term Debt	-0.35	0.06	-0.32	0.93	-0.5	-0.19	0.36	0.47	0.32	0.05	-0.37	0.46	0.95	-0.37	0.18	0.18	-0.34	-0.57	-0.34	-0.34	0.15	-0.19	-0.38		-0.34	-0.17
Intangible Assets	0.83	0.54	0.74	-0.11	0.8	0.71	0.2	-0.78	-0.8	0.63	0.81	0.33	-0.34	0.81	-0.67	0.71	0.98	0.62	0.81	0.92	0.52	0.74	0.83	-0.34		0.76
Common Stock	0.7	0.73	0.89	0.13	0.55	0.82	0.44	-0.51	-0.92	0.85	0.66	0.5	-0.09	0.66	-0.76	0.54	0.85	0.69	0.67	0.87	0.72	0.82	0.68	-0.17	0.76

Click cells to compare fundamentals

Exagen Account Relationship Matchups

Exagen fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	88.3M	78.4M	123.4M	86.2M	56.9M	54.2M
Short Long Term Debt Total	25.9M	26.7M	27.5M	34.5M	23.7M	23.8M
Other Current Liab	4.2M	5.4M	6.2M	5.3M	7.0M	4.0M
Total Current Liabilities	5.9M	8.8M	9.3M	9.6M	11.9M	9.7M
Total Stockholder Equity	55.7M	41.8M	84.9M	42.5M	22.7M	20.5M
Property Plant And Equipment Net	1.4M	2.1M	4.8M	13.1M	8.5M	8.9M
Net Debt	(46.2M)	(30.8M)	(72.0M)	(27.9M)	(12.8M)	(13.4M)
Retained Earnings	(164.6M)	(181.3M)	(208.1M)	(255.5M)	(279.2M)	(265.3M)
Accounts Payable	1.5M	3.0M	2.5M	3.0M	3.1M	2.1M
Cash	72.1M	57.4M	99.4M	62.4M	36.5M	37.0M
Non Current Assets Total	7.1M	7.9M	10.7M	13.6M	9.1M	10.2M
Non Currrent Assets Other	503K	174K	(487K)	(391K)	528K	416K
Cash And Short Term Investments	72.1M	57.4M	99.4M	62.4M	36.5M	37.0M
Common Stock Shares Outstanding	12.6M	12.7M	16.0M	17.1M	17.7M	18.6M
Liabilities And Stockholders Equity	88.3M	78.4M	123.4M	86.2M	56.9M	54.2M
Non Current Liabilities Total	26.8M	27.8M	29.2M	34.1M	22.3M	20.3M
Other Current Assets	3.5M	4.2M	3.6M	4.1M	1.9M	2.1M
Other Stockholder Equity	220.2M	223.1M	293.1M	298.0M	301.9M	164.6M
Total Liab	32.7M	36.5M	38.5M	43.8M	34.3M	33.7M
Property Plant And Equipment Gross	1.4M	2.1M	4.8M	13.1M	14.3M	15.0M
Total Current Assets	81.3M	70.5M	112.7M	72.6M	47.8M	44.0M
Short Term Debt	238K	308K	587K	1.2M	1.7M	1.6M
Other Assets	174K	250K	433K	528K	475.2K	894.3K
Net Receivables	5.7M	8.9M	9.7M	6.1M	6.6M	6.0M
Property Plant Equipment	1.4M	2.1M	4.8M	13.1M	15.0M	15.8M
Other Liab	266K	530K	1.7M	19K	17.1K	16.2K
Net Tangible Assets	50.2M	36.3M	79.4M	42.5M	48.8M	51.3M
Long Term Debt	25.9M	26.7M	27.5M	28.8M	19.2M	21.0M
Capital Lease Obligations	238K	308K	587K	6.2M	4.2M	4.4M
Inventory	1.4M	1.2M	1.1M	1.8M	2.9M	3.0M
Non Current Liabilities Other	638K	948K	1.4M	867K	357K	567.1K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock:

How To Invest In Exagen

Details

Is Exagen Stock a good investment?

Details

What is Exagen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

Note that the Exagen Inc information on this page should be used as a complementary analysis to other Exagen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Exagen Stock analysis

When running Exagen's price analysis, check to measure Exagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exagen is operating at the current time. Most of Exagen's value examination focuses on studying past and present price action to predict the probability of Exagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Exagen's price. Additionally, you may evaluate how the addition of Exagen to your portfolios can decrease your overall portfolio volatility.

	Commodity Directory Find actively traded commodities issued by global exchanges
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Fundamental Analysis View fundamental data based on most recent published financial statements
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like

Is Exagen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.34)

Revenue Per Share

2.972

Quarterly Revenue Growth

0.072

Return On Assets

(0.20)

Return On Equity

(0.73)

The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Exagen Total Liab vs Current Deferred Revenue Analysis

Total Liab vs Current Deferred Revenue

Total Liab vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Total Liab

Current Deferred Revenue

Exagen fundamental ratios Correlations

Exagen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Exagen fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Exagen Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Net Debt	- 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	- 0.98	Good Will
Cash And Short Term Investments	- 0.95	Net Debt
Cash	- 0.95	Net Debt
Total Current Assets	- 0.94	Net Debt
Good Will	- 0.94	Property Plant And Equipment Net